MedTrace Logo

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

NCT05917587 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-13

No results posted yet for this study

Summary

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.

Conditions

  • Gestational Diabetes

Interventions

DRUG

Metformin Hydrochloride

12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.

OTHER

placebo

12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.

Sponsors & Collaborators

  • Anna Stanhewicz, PhD

    lead OTHER

Principal Investigators

  • Anna Stanhewicz, PhD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2027-12-31
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05917587 on ClinicalTrials.gov